Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Wall Street analysts rushed to defend Viking Therapeutics on Tuesday after topline results from its Phase 2 Venture-Oral ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...